Bile Duct Cancer, Bladder Cancer, Breast Neoplasm Malignant Primary, Cervical Cancer, Cholangiocarcinoma, Colo-rectal Cancer, Head and Neck Cancer, Head and Neck Carcinoma, HER-2 Gene Amplification, HER2 Gene Mutation, HER2-positive Breast Cancer, HER2 Positive Gastric Cancer, Larynx Cancer, Lip Cancer Stage I, Liver Cancer, Lung Cancer, Mouth Cancer, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Mucoepidermoid Carcinoma, Palate Cancer, Pancreatic Cancer, Primary Peritoneal Carcinoma, Prostate Cancer, Rare Diseases, Rectal Cancer, Rectal Cancer Stage I, Rectal Cancer Stage II, Rectal Cancer Stage III, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Carcinoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Salivary Gland Cancer, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Salivary Gland Tumor, Skin Cancer, Solid Tumor, Tongue Cancer, Tonsil Cancer, Urologic Cancer
Conditions
Brief summary
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.
Detailed description
This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing (NGS) or HER2 expression, defined as at least 1+ by validated immunohistochemistry (IHC) test. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. Patients will receive study drug as a single IV infusion at the prescribed dose level in each treatment cycle. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).
Interventions
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Sponsors
Study design
Eligibility
Inclusion criteria
Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male or female patient ≥ 18 years. 3. Histologically documented, incurable, locally advanced or metastatic cancer. 4. Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC. 5. Patients should have no available therapy likely to convey clinical benefit. 6. Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL. 7. Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN). 8. Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed. 9. ECOG Performance Status ≤ 1. 10. Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy. 11. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
Exclusion criteria
Phase I: 1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia). 2. History of Grade ≥ 3 hypersensitivity reaction to trastuzumab. 3. History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued. 4. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug. 5. Require supplemental oxygen for daily activities. 6. Documented Grade ≥ 2 peripheral neuropathy. 7. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug. 8. Any experimental therapy within 4 weeks of first infusion of study drug. 9. Any major surgical procedure within 4 weeks of first infusion of study drug. 10. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded. 11. Have known prior positive test results for human immunodeficiency virus. 12. Uncontrolled hypertension or diabetes. 13. Pregnancy or lactation. 14. Resting corrected QT interval (QTc) \> 470 ms at baseline. 15. Left ventricular ejection fraction (LVEF) \< 45% determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. 16. Prior cumulative doxorubicin dose of \> 360 mg/m2 or equivalent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I: Maximum Tolerated Dose | Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Number of patients with dose limiting toxicities |
Secondary
| Measure | Time frame |
|---|---|
| Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. | Every 3 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Phase I: Number of participants who developed measurable anti-drug antibodies | Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Phase I Maximum observed serum or plasma concentration (Cmax). | 84 Days from date of first dose |
| Phase I Clearance (CL). | 84 Days from date of first dose |
| Phase I: Number of patients with Dose Limiting Toxicities | Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Phase I Terminal phase elimination half life (t½). | 84 Days from date of first dose |
| Phase I Volume of distribution at terminal phase (Vz). | 84 Days from date of first dose |
| Phase I Volume of distribution at steady state (Vss). | 84 Days from date of first dose |
| Phase I Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-∞]). | 84 Days from date of first dose |
Countries
United States